Loading
Life sciences · Journal article
International Journal of Molecular Sciences · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Volvariella volvacea is a widely consumed edible mushroom, yet the lipid-lowering potential of its polysaccharides remains poorly understood. In this study, two polysaccharide-enriched fractions, VVP-1 and VVP-2, were isolated from V. volvacea fruiting bodies, with weight-average molecular weights of 13,789 and 17,829 Da, respectively. Their lipid-lowering effects were evaluated in palmitic acid (PA)-challenged AML12 mouse hepatocytes and in high-fat diet (HFD)-induced obese male C57BL/6J mice. Both fractions reduced PA-induced intracellular triglyceride (TG) levels in a dose-dependent manner, with VVP-2 showing a trend of greater efficacy. At the molecular level, VVP-2 exposure was associated with downregulation of the lipogenic genes Acaca and Srebf1, upregulation of the fatty acid oxidation-related genes Cpt1a and Ppara, decreased secretion of TNF-α, IL-6, and IL-1β, preservation of mitochondrial signal, restoration of mitochondrial membrane potential, and enhanced ATP production. In HFD-fed mice, VVP-2 (100 mg/kg) attenuated body-weight gain by 38.9%, reduced liver weight by 28.9% and epididymal, inguinal, and perirenal fat weights by 50.3%, 47.5%, and 28.8%, respectively, improved the serum lipid profile (TG reduced by 39.1%, TC by 33.5%, NEFA by 56.2%, and LDL-C by 56.8%), and alleviated hepatic lipid accumulation and liver injury. These findings suggest that VVP-2 may improve mitochondrial function and modulate lipid metabolism-related gene expression, potentially reducing lipid accumulation and inflammation in hepatocytes. These results support the potential of VVP-2 as a lipid-lowering functional food ingredient for the prevention of metabolic dysfunction-associated steatotic liver disease.